HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mead DHA/ARA-Fortified Infant Formula Slated For February Release

This article was originally published in The Tan Sheet

Executive Summary

Mead Johnson Nutritionals' Enfamil LIPIL, an infant formula fortified with ARA and DHA fatty acid oils, will be priced in the U.S. at a 10%-15% premium to the line's Enfamil with Iron product, the firm said

You may also be interested in...



Martek Fiscal 2002 Sales Jump 144.7%; WIC Acceptance Aids Growth

Infant formulas fortified with Martek Biosciences' DHA and ARA fatty acids have been accepted by the WIC program in roughly 15 states, Chief Executive Officer Henry Linsert said in a Dec. 12 analysts call

Martek Revenue Could Double, Reach $90 Mil. In FY 2003, CEO Says

Martek Biosciences expects to double its penetration in both domestic and international infant formula markets by next year, company execs said during a June 6 analysts' call

Supplement, Infant Formula Acceptable Claims Not Equivalent – NCL

Claims approved for dietary supplements containing DHA may not be suitable for DHA- and ARA-fortified infant formulas, the National Consumers League says in a Feb. 5 letter to the National Advertising Division of the Council of Better Business Bureaus

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel